The European Commission is reportedly in advanced discussions with French biotech Valneva about picking up the contract to supply COVID-19 vaccines that was terminated by the UK government this week.

an inactivated whole-virus COVID-19 vaccine. Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings ...

Valneva SE is a vaccine company focused on ... distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable ...

Valneva has bolstered its vaccines pipeline ... The French pharma company – best known for its COVID-19 jab and recent approval for the world's first chikungunya vaccine Ixchiq – is paying ...

During the emergence of the COVID-19 pandemic, Associate Professor Björn Reinius at ... now produced by the French biotech company Valneva. This vaccine addresses a major public health need by ...

Shares of Valneva SE (NASDAQ:VALN – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $6.86, but opened at $7.11. Valneva shares last traded at $ ...

Valneva has met its revenue growth target for 2024, fending off slower-than-expected sales for the chikungunya vaccine Ixchiq. The French vaccine specialist posted total revenues of €169.6m ($ ...

Saint-Herblain (France), March 3, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that its senior management will participate at upcoming ...